Hypoxia-targeting by tirapazamine (TPZ) induces preferential growth inhibition of nasopharyngeal carcinoma cells with Chk1/2 activation Bo HongVivian W. Y. LuiAnthony Tak-Cheung Chan PRECLINICAL STUDIES 16 December 2009 Pages: 401 - 410
Cell death induced by novel fluorinated taxanes in drug-sensitive and drug-resistant cancer cells Jana VobořilováVlasta Němcová-FürstováJan Kovář PRECLINICAL STUDIES 16 December 2009 Pages: 411 - 423
Preclinical investigation of tolerance and antitumour activity of new fluorodeoxyglucose-coupled chlorambucil alkylating agents Elisabeth Miot-NoiraultBastien ReuxValérie Weber PRECLINICAL STUDIES 23 December 2009 Pages: 424 - 433
Antitumor efficacy and apoptotic activity of substituted chloroalkyl 1H-benz[de]isoquinoline-1,3-diones: a new class of potential antineoplastic agents Asama MukherjeeSuva HazraUtpal Sanyal PRECLINICAL STUDIES 12 January 2010 Pages: 434 - 442
Preparation, characterisation and preliminary antitumour activity evaluation of a novel nanoparticulate system based on a cisplatin-hyaluronate complex and N-trimethyl chitosan Sergio CafaggiEleonora RussoMaurizio Viale PRECLINICAL STUDIES 29 December 2009 Pages: 443 - 455
Antiproliferative activity, mechanism of action and oral antitumor activity of CP-4126, a fatty acid derivative of gemcitabine, in in vitro and in vivo tumor models Andries M. BergmanAuke D. AdemaGodefridus J. Peters PRECLINICAL STUDIES Open access 12 January 2010 Pages: 456 - 466
A phase I study of ispinesib, a kinesin spindle protein inhibitor, administered weekly for three consecutive weeks of a 28-day cycle in patients with solid tumors Howard A. Burris IIISuzanne F. JonesPatricia LoRusso PHASE I STUDIES 13 January 2010 Pages: 467 - 472
Phase I study of 17-allylamino-17 demethoxygeldanamycin, gemcitabine and/or cisplatin in patients with refractory solid tumors Joleen HubbardCharles ErlichmanPaul Haluska PHASE I STUDIES 15 January 2010 Pages: 473 - 480
Efficacy and safety of sorafenib in a subset of patients with advanced soft tissue sarcoma from a Phase II randomized discontinuation trial Simon PaceyMark J. RatainI. R. Judson PHASE II STUDIES 18 December 2009 Pages: 481 - 488
A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naïve patients with advanced melanoma Evan M. HershSteven J. O’DayJeffrey S. Weber PHASE II STUDIES 16 January 2010 Pages: 489 - 498
Pharmacokinetic study of the phase III, randomized, double-blind, multicenter trial (TRIBUTE) of paclitaxel and carboplatin combined with erlotinib or placebo in patients with advanced Non-small Cell Lung Cancer (NSCLC) Hai T. TranRalph G. ZinnerRoy S. Herbst PHASE III STUDIES 22 January 2010 Pages: 499 - 505
ATP chemosensitivity testing of new antitumor duplex drugs linking 3`-C-ethynylycytidine (ECyd) and 2´-deoxy-5-fluorouridine (5-FdU) in comparison to standard cytostatica and combinations thereof Sarah SchottMarkus WallwienerHans Neubauer SHORT REPORT 09 December 2009 Pages: 506 - 513
A novel Chk inhibitor, XL-844, increases human cancer cell radiosensitivity through promotion of mitotic catastrophe Oliver RiestererFumihiko MatsumotoUma Raju SHORT REPORT 22 December 2009 Pages: 514 - 522